Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.

Download Full-text

Faculty Opinions recommendation of Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738393902.793577472 ◽

2020 ◽

Author(s):

Anita L Nelson

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Cancer Incidence ◽

Randomized Clinical Trials ◽

Breast Cancer Incidence ◽

Health Initiative ◽

Incidence And Mortality ◽

Long Term Follow Up

Download Full-text

Abstract 4692: Local adjuvant treatment of clinical stage I-II melanoma with low dose CpG-B and/or GM-CSF: Long-term follow-up of three randomized controlled phase II trials

10.1158/1538-7445.am2017-4692 ◽

2017 ◽

Author(s):

Bas D. Koster ◽

Mari F. van den Hout ◽

Berbel J. Sluijter ◽

Barbara G. Molenkamp ◽

Ronald J. Vuylsteke ◽

...

Keyword(s):

Phase Ii ◽

Adjuvant Treatment ◽

Low Dose ◽

Clinical Stage ◽

Phase Ii Trials ◽

Gm Csf ◽

Randomized Controlled ◽

Long Term Follow Up

Download Full-text

Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up

Experimental and Therapeutic Medicine ◽

10.3892/etm.2015.2293 ◽

2015 ◽

Vol 9 (4) ◽

pp. 1545-1556 ◽

Cited By ~ 2

Author(s):

QI WANG ◽

YU ZHOU ◽

TONG QIAO ◽

MIN ZHOU

Keyword(s):

Clinical Trials ◽

Randomized Clinical Trials ◽

Clinical Performance ◽

Meta Analysis ◽

Drug Eluting Stents ◽

Long Term Follow Up ◽

Drug Eluting

Download Full-text

Abstract 2140: Differential Efficacy and Safety of Drug-Eluting Stents With Short Versus Long Term Follow-up: A Meta-Analysis of Randomized Clinical Trials

Circulation ◽

10.1161/circ.116.suppl_16.ii_464 ◽

2007 ◽

Vol 116 (suppl_16) ◽

Author(s):

Henri Roukoz ◽

Anthony A Bavry ◽

Michael L Sarkees ◽

Dharam J Kumbhani ◽

Mark G Rabbat ◽

...

Keyword(s):

Clinical Trials ◽

Stent Thrombosis ◽

Randomized Clinical Trials ◽

Drug Eluting Stents ◽

All Cause Mortality ◽

Long Term Follow Up ◽

Drug Eluting ◽

Q Wave

Introduction: Drug eluting stents (DES) significantly reduce target lesion revascularization (TLR) compared to bare metal stents (BMS) within 1 year of follow-up, however they increase late stent thrombosis. The effect of DES on the need for late revascularization is unclear. Hypothesis: We sought to evaluate the safety and efficacy of DES compared to BMS early after intervention (< 1 year) and late (> 1 year) among both stable patients and acute coronary syndromes. Methods: We searched the Medline database for randomized clinical trials with long-term follow-up, from 2000 to 2007. We also searched relevant journal supplements for abstracts and obtained trial presentations from cardiology meetings. Results: We identified 24 trials (17% acute coronary syndrome patients) with a total of 10,278 patients. The weighted mean duration of follow-up was 28 months. For early outcomes (< 1 year); the incidence of all-cause mortality for DES vs. BMS was 2% vs. 2.1%, RR=0.95, 95%CI (0.70–1.27), p=0.7, cardiovascular mortality was 1.4% vs. 1.5%, RR=0.95 (0.73–1.24), p=0.72, Q-wave myocardial infarction (MI) was 0.8% vs. 0.6%, RR= 1.24 (0.7–2.2), p=0.45, non-Q-wave MI was 3% vs. 4%, RR=0.73 (0.55–0.96), p=0.024, TLR was 5.9% vs. 17.8%, RR=0.29 (0.24–0.34), p<0.001, and stent thrombosis was 0.94% vs. 1.1%, RR=0.83 (0.55–1.27), p=0.4. For late outcomes (>1 year); the incidence of all-cause mortality for DES vs. BMS was 3.9% vs. 3.8%, RR=1.04 (0.79–1.38), p=0.7, cardiovascular mortality 1.4% vs. 1.5%, RR=0.95 (0.73–1.24), p=0.72, Q-wave MI was 0.7% vs.0.6%, RR=1.05 (0.54–2.05), p=0.87, non-Q-wave MI was 1.6% vs. 1.2%, RR=1.39 (0.87–2.21), p=0.16, TLR was 2.6% vs. 3.2%, RR=0.82 (0.59–1.13), p=0.23, and stent thrombosis was 0.59% vs. 0.15%, RR=3.2 (1.22–8.36), p=0.018. Conclusions: Within 1 year of follow-up, DES appears to be safe and efficacious with similar mortality, similar stent thrombosis, decreased TLR, and decreased non-Q-wave MI compared to BMS. After 1 year, DES still has similar mortality compared to BMS, however TLR, while low, is no longer reduced, stent thrombosis is increased, and there is a numerical excess of non-Q-wave MI.

Download Full-text